American Association for Cancer Research
15357163mct121226t-sup-fig_2_pdf248k.pdf (248.24 kB)

Supplementary Figure 2 from Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner

Download (248.24 kB)
journal contribution
posted on 2023-04-03, 14:12 authored by Michaël Cerezo, Mélanie Tichet, Patricia Abbe, Mickaël Ohanna, Abdelali Lehraiki, Florian Rouaud, Maryline Allegra, Damien Giacchero, Philippe Bahadoran, Corine Bertolotto, Sophie Tartare-Deckert, Robert Ballotti, Stéphane Rocchi

PDF - 248K, A375, 1205Lu or patient melanoma cells were treated 24h with metformin (at the indicated concentrations), 2h with staurosporine (1 microM) or PBS, lysed and analysed by Western-blot with PARP and caspase 3 antibodies.



Metformin was reported to inhibit the proliferation of many cancer cells, including melanoma cells. In this report, we investigated the effect of metformin on melanoma invasion and metastasis development. Using different in vitro approaches, we found that metformin inhibits cell invasion without affecting cell migration and independently of antiproliferation action. This inhibition is correlated with modulation of expression of proteins involved in epithelial–mesenchymal transition such as Slug, Snail, SPARC, fibronectin, and N-cadherin and with inhibition of MMP-2 and MMP-9 activation. Furthermore, our data indicate that this process is dependent on activation of AMPK and tumor suppressor protein p53. Finally, we showed that metformin inhibits melanoma metastasis development in mice using extravasation and metastasis models. The presented data reinforce the fact that metformin might be a good candidate for clinical trial in melanoma treatment. Mol Cancer Ther; 12(8); 1605–15. ©2013 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager